

Multi-center, Open-label, Single-ascending Dose Study of Safety and Tolerability of TN-201 in Adults With Symptomatic MYBPC3 Mutation-associated HCM

NCT05836259

Status	RECRUITING
Phase	Phase 1, Phase 2
Sponsor	Tenaya Therapeutics
Enrollment	30 participants

Key Eligibility Criteria

Inclusion (5)

- MYBPC3 mutation
- Hypertrophic Cardiomyopathy (obstructive and nonobstructive)
- Left Ventricular Ejection Fraction \geq 45%
- NYHA Functional Class II or III symptoms
- NT-proBNP \leq 160pg/ml

Exclusion (1)

- High AAV9 neutralizing antibody titer

Locations (10 total)

UC San Diego Altman Clinical and Translational Research Institute - Center for Clinical Research, La Jolla, California, United States
University of California San Francisco, San Francisco, California, United States
Emory University, Atlanta, Georgia, United States
... and 7 more locations

<https://clinicaltrials.gov/study/NCT05836259>

DISCLAIMER: This document is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider before enrolling in any clinical trial. Information may not be up to date — verify details at [ClinicalTrials.gov](https://clinicaltrials.gov). Generated by [ClinicalTrialsFinder.org](https://clinicaltrialsfinder.org).